A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

PHASE2CompletedINTERVENTIONAL

Enrollment

848

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2006

Conditions

Urinary Incontinence

Interventions

DRUG

MK-0634 50 mg

one capsule orally, once daily in morning

DRUG

MK-0634 125 mg

one or three capsules orally, once daily in morning

DRUG

Placebo for MK-0634

one, two, three or four capsules orally once daily in morning

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00231790 - A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) | Biotech Hunter | Biotech Hunter